Elsevier

Biochemical Pharmacology

Volume 49, Issue 12, 16 June 1995, Pages 1777-1784
Biochemical Pharmacology

Research paper
In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron

https://doi.org/10.1016/0006-2952(95)00021-QGet rights and content

Abstract

The new 5-hydroxytryptamine type 3 (5HT3) receptor antagonist tropisetron is used in the treatment of chemotherapy-related nausea. The drug is extensively metabolized in man, with the enzymes involved in tropisetron biotransformation being unknown. Identification of these enzymes would make it possible to predict both interindividual variability in plasma concentrations and metabolic interaction potential. The present in vitro study was therefore aimed at identifying and characterizing the cytochrome P450 enzymes catalysing tropisetron metabolism. Enzyme kinetics for formation of 5-hydroxy (5-OH-ICS), 6-hydroxy (6-OH-ICS) and N-demethyl tropisetron (N-De-ICS) were studied in the microsomal fraction of eight human livers (seven livers from extensive metabolizer (EM), one liver from a poor metabolizer (PM) for CYP2D6). Formation of 5-OH-ICS and 6-OH-ICS was biphasic with a high (5-OH: Km 3.9 ± 2.1 μM; Vmax 1.88 ± 0.73 pmol/mg/min; 6-OH: Km 4.66 ± 1.84 μM; Vmax 4.00 ± 1.77 pmol/mg/min) and low (5-OH: Km 172 ± 51 μM; Vmax 17.0 ± 9.4 pmol/mg/min; 6-OH: Km 266.0 ± 76.0 μM; Vmax 81.4 ± 27.9 pmol/mg/min) affinity component. The high-affinity component was identified as CYP2D6 which exhibits a genetic polymorphism in man. This component was absent in the PM liver. The low-affinity component was present in EM and PM livers and was identified as CYP3A4. LKM1 antibodies directed against CYP2D6 completely inhibited the high affinity component. Quinidine (0.5 μM) inhibited 5- and 6-hydroxylation at 10–80 μM tropisetron concentrations competitively by 70% with Ki values of 10 and 18 nM, respectively. Stably-expressed CYP2D6 catalysed the formation of both 5-OH-ICS and 6-OH-ICS. Both inhibition experiments and use of stablyexpressed enzymes revealed formation of N-De-ICS to be mediated by CYP3A4. Based on in vitro intrinsic clearances CYP2D6-catalysed 5-OH-ICS and 6-OH-ICS is the predominant route of tropisetron elimination. Large phenotype-related differences in total clearance are to be expected after administration of tropisetron. However, in view of the wide therapeutic index of tropisetrone and the rather high Ki for inhibition of the metabolism of other drugs by tropisetron, both the interindividual variability and the interaction potential appear to be of no clinical relevance.

References (32)

  • L Dogliotti et al.

    Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients

    Drugs

    (1992)
  • U Bruntsch et al.

    Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy

    Drugs

    (1992)
  • H Bleiberg et al.

    Compassionate use of a 5 HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment

    Drugs

    (1992)
  • B Sorbe et al.

    Tropisetron, a new 5 HT3-receptor antagonist, in the prevention of radiationinduced nausea, vomiting and diarrhoea

    Drugs

    (1992)
  • KMW Pister et al.

    Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy

    Cancer

    (1993)
  • KM De Bruijn

    Tropisetron: A review of the clinical experience

    Drugs

    (1992)
  • Cited by (36)

    • CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

      2022, Expert Opinion on Drug Metabolism and Toxicology
    View all citing articles on Scopus
    View full text